Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.
Effects of intranasal administration of cholera toxin (CT) [or Escherichia coli heat-labile enterotoxin (LT)] B subunits supplemented with a trace amount of the holotoxin, CTB* or LTB*, on the brain were examined in BALB/c mice by comparing with those of the intracerebral injection. Intracerebral injection of CTB* at doses more than 10 microg/mouse caused significant body weight loss and dose-dependent death within 7 days, with localization of conjugates of horseradish peroxidase with CTB (HRP-CTB) in the ventricular system and in the perineural space of olfactory nerves of the nasal mucosa 3 h after injection. Intracerebral injection of CTB* at doses less than 3 microg/mouse (or LTB* at doses less than 22.7 microg/mouse) did not cause any significant body weight loss for 7 days, with localization of HRP-CTB in the brain but not in the nasal mucosa. On the other hand, intranasal administration of 10 microg of CTB* caused localization of HRP-CTB in the nasal mucosa but not in the brain 3 h after administration and caused body weight loss even after 30 administrations. Neither any histological changes of brain tissues nor marked changes in serum biochemical parameters were found in mice after the 30 administrations of CTB* or LTB*. These results suggest that 0.1 microg of CTB* or LTB*, which is known to be close to the minimal effective dose as an adjuvant for nasal influenza vaccine in mice and corresponds to 100 microg per person, can be used as a safe nasal adjuvant without adversely affecting the brain.
Hagiwara
Y
Y
Department of Pathology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, 162-8640, Tokyo, Japan.
Iwasaki
T
T
Asanuma
H
H
Sato
Y
Y
Sata
T
T
Aizawa
C
C
Kurata
T
T
Tamura
S
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity; D000281:Administration, Intranasal; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002772:Cholera Toxin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004768:Enterotoxins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000633:toxicity; D004926:Escherichia coli; D005260:Female; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity; D006735:Horseradish Peroxidase; D018928:Immunity, Mucosal; D007276:Injections, Intraventricular; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000187:drug effects / Q000294:innervation / Q000378:metabolism / Q000473:pathology; D009832:Olfactory Nerve / Q000187:drug effects; D021122:Protein Subunits; D015996:Survival Rate; D014315:Triterpenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000633:toxicity
D000276:Adjuvants, Immunologic; D001798:Blood Proteins; D004768:Enterotoxins; D006027:Glycosides; D021122:Protein Subunits; D014315:Triterpenes; C001883:stichoposide; D002772:Cholera Toxin; D006735:Horseradish Peroxidase